ommends the addition of Hib vaccine to immunization programs, according to national capacities and priorities [7] . However, uptake in developing countries has remained slow. This is due partly to the cost of Hib vaccine and partly to uncertainty about the true disease burden.
Measuring Hib disease burden is not straightforward. In developing countries, pneumonia is the most common Hib disease, but the etiology of pneumonia is difficult to determine, except in that minority of patients who also have blood cultures positive for Hib (i.e., bacteremic pneumonia). By contrast, approximately two-thirds of patients with Hib meningitis are bacteremic at presentation. Meningitis can be easily measured through Hib meningitis surveillance, provided that lumbar punctures (LPs) are performed on most children with possible meningitis prior to the administration of antibiotics and that laboratory facilities are adequate. Hib is a fastidious organism, so identification is highly dependent on the procedures and ma-terials used in the laboratory. Isolation of Hib can be compromised by delayed transportation of specimens to the laboratory; use of human blood rather than sheep blood for culture; and the lack of specific, relatively expensive growth factors.
An alternative method of estimating the Hib disease burden is to undertake vaccine probe studies to determine the number of cases of pneumonia and meningitis prevented in Hib-vaccinated children [8, 9] . Such studies have estimated the ratio of the number of Hib meningitis cases prevented to the number of Hib pneumonia cases prevented. This ratio can be applied to other sites where the incidence of Hib meningitis is known, and, therefore, using this ratio, Hib pneumonia rates may be estimated [10] . A less precise method is to compare disease incidence rates before and after Hib vaccine introduction. This would be unsuitable for pneumonia, for which clinical definitions are notoriously inconsistent, but it can provide useful information for meningitis [5] , provided case detection, investigation, and laboratory procedures are consistent over a prolonged period of time. Methods that use the effectiveness of the vaccine to estimate the burden of Hib disease rely on assumptions about vaccine efficacy, which is well described for the prevention of meningitis but is not known for the prevention of pneumonia. If the true vaccine efficacy for the prevention of pneumonia is less than expected, the disease burden estimates derived from these methods will be underestimates.
Because of inherent difficulties in measuring Hib disease burden, WHO has developed an Hib Rapid Assessment Tool (RAT) that uses existing data to estimate the number of cases and deaths due to Hib meningitis and Hib pneumonia [11] . The Hib RAT provides 2 methods for estimating Hib disease burden: first, the meningitis incidence rate method, based on cases of culture-confirmed meningitis, and, second, the under-5 mortality rate method, based on the overall mortality rate among children !5 years old [11] .
Nine of 20 Pacific island countries (PICs) have not yet added Hib vaccine to their immunization programs. The populations of these 9 islands include each of the 3 major ethnic groups in the region: Polynesian (found in the Cook Islands, Nauru, Samoa, Tokelau, Tonga, and Tuvalu), Melanesian (found in the Solomon Islands and Vanuatu), and Micronesian (found in Kiribati). To assist these countries in deciding about the value of introducing the Hib vaccine to their immunization programs, the Hib disease burden was estimated in a subset of countries to provide a regional estimate.
METHODS
To estimate the burden of Hib in PICs, existing reports and publications were requested from each of the 9 PICs, a Medline literature search was performed, and 4 site visits were undertaken. During the site visits, data were collected to allow the burden of Hib to be estimated using the WHO RAT. The Medline search strategy used the terms "Haemophilus influenzae type b," "Hib," the name of each individual PIC, and "Micronesia," "Melanesia," or "Polynesia." The search included all articles published in the English language from 1966 through July 2002. The PICs visited were selected on the basis of having a population of 180,000 and the availability of hospital and laboratory data, and were selected with the aim of having у1 estimate from each of the 3 ethnic groups. The PICs selected were Kiribati (in Micronesia), the Solomon Islands (in Melanesia), and Samoa and the Kingdom of Tonga (in Polynesia).
Calculation of Hib disease incidence during site visits. The laboratories in all of the countries visited (except for those in Kiribati) were not able to type Haemophilus influenzae (Hi); therefore, 95% of Hi isolates were assumed to be Hib [1] . To calculate the annual Hi or Hib disease incidence in children aged !5 years, the proven Hi or Hib meningitis incidence was calculated on the basis of CSF or blood cultures that were positive for Hib and associated with cases of clinical meningitis. The incidence of proven invasive Hi disease (defined as a positive culture of blood or CSF samples in conjunction with any clinical presentation of symptoms) was also calculated, where possible. Lumbar puncture (LP) rates were estimated by calculating the proportion of patients with clinical cases of meningitis who had LPs performed. An LP was considered to have been performed if it was documented in either the patient's laboratory records or their medical records. Hib disease burden estimates were then calculated using the 2 methods outlined in the Hib RAT [11] . Briefly, by the meningitis incidence method, the number of Hib meningitis cases is determined for a known population over a defined period. The annual number of Hib meningitis cases is then adjusted to account for the proportion of individuals with cases of suspected meningitis who do not undergo LP and the proportion of individuals with cases of purulent meningitis and cultures negative for Hib, producing an adjusted Hib meningitis incidence rate. The number of Hib pneumonia cases is then estimated by assuming an Hib pneumonia/Hib meningitis ratio of . The number of deaths is calculated using the local Hib 5:1 meningitis case fatality rates and assuming an Hib pneumonia case fatality rate of 5% or 10%. The Hib meningitis case fatality rate was estimated from local Ministry of Health and pediatric discharge data and was set at 10% for Solomon Islands and Tonga, 14% for Samoa, and 17% for Kiribati. The reliability of this estimate may be affected by poor access to health care, with an unknown-but high-case fatality rate for untreated cases affecting overall mortality. However, child mortality rates in the PICs (apart from the Solomon Islands) are low, and very few children were thought to die before reaching the hospital. The Hib pneumonia case fatality rate was either 5% or 10%, depending on the PIC. This was not based on local data and is estimated from the proportion of deaths caused by acute respiratory infections and from the proportion of these deaths that may be caused by Hib [11] . The under-5 mortality rate method (using postneonatal mortality rates) estimates the number of Hib pneumonia cases and deaths from the proportion of deaths due to pneumonia and the proportion of pneumonia cases that are due to Hib, on the basis of the under-5 mortality rate [11] . Then, assuming a 5% or 10% case fatality rate for Hib pneumonia, the number of Hib pneumonia cases is estimated, and, assuming the same Hib pneumonia/Hib meningitis ratio (5:1), the Hib meningitis rate is then calculated. The under-5 mortality rate method could not be used for Kiribati, as no under-5 or neonatal mortality rate data were available.
Both methods lead to an estimate of incidence and of the number of cases and deaths attributable to Hib meningitis and pneumonia in children !5 years old [11] . Both methods make important assumptions, although the under-5 mortality rate method relies on more assumptions than does the meningitis incidence rate method. Key assumptions include the ratio of cases of Hib pneumonia to cases of Hib meningitis. This ratio is set at , on the basis of data from Hib vaccine trials in the 5:1 Gambia and Chile [8, 9] . There are no comparable data from countries with lower child mortality rates, such as PICs, where the ratio is likely to be lower. In developed countries, where pneumonia is less common, the ratio is probably !1:1. Therefore, we performed a sensitivity analysis using a more conservative ratio of 1:1 to calculate the number of Hib cases and deaths. Denominator data came from the most recent local census data without growth projections. Care was taken to confirm the domicile of each patient to ensure that only patients from the catchment population were included.
RESULTS

Hib disease burden.
Culture-confirmed Hi meningitis incidence rates were 52 cases per 100,000 children !5 years old per year in Tonga, 33 cases per 100,000 children !5 years old per year in the Solomon Islands, and 25 cases per 100,000 children !5 years old per year in Samoa (table 1) . Kiribati had a single Hib isolate, giving a rate of 11 cases of Hib per 100,000 children !5 years old. In Tonga, the 13 Hi isolates comprised isolates obtained from 7 patients with culture-positive CSF samples, 6 patients with Hi-positive blood cultures, 4 of whom did not have an LP performed (but had clinical meningitis) and 2 of whom had sterile and purulent CSF samples. In addition, another 5 patients with cases of invasive Hi disease were identified from blood culture isolates, including 4 patients with cases of pneumonia. Including these cases, the incidence of all culture-confirmed invasive Hi disease in Tonga was 71 cases per 100,000 children !5 years old (95% CI, 42-113).
The laboratory methods used were not optimal. All laboratories used expired human blood to make chocolate blood agar for culture of CSF samples and for the subculture of positive blood cultures. LP rates were 50% of patients for Kiribati, 90% for the Solomon Islands, 69% for Samoa, and 81% for Tonga. The Hib RAT adjusts for these potential missed patients (i.e., those patients that either did not have an LP performed or for whom the laboratory methods were suboptimal for isolating Hib). This gave estimates of 70-84 cases per 100,000 children !5 years old in 3 PICs (table 2). The estimate for Kiribati was consistent with the other 3 PICs, although this estimate was based on only a single isolate.
The estimates obtained for Tonga, the Solomon Islands, and Samoa were lower using the under-5 mortality rate method than using the meningitis incidence rate method (table 3) . In Tonga, the estimated Hib meningitis incidence using the under-5 mortality rate method was even lower than was the proven Hi culture-based incidence (table 1) .
A sensitivity analysis was performed using both of the Hib RAT methods and a more conservative Hib pneumonia/Hib meningitis ratio of 1:1. In Tonga, where the mortality rate among children !5 years old is low (15.5 deaths per 1000 live births) and blood and CSF samples were cultured in a consistent and timely fashion, use of the Hib pneumonia/Hib meningitis ratio of 1:1 results in an Hib meningitis incidence estimate of 69 cases per 100,000 children !5 years old, using the under-5 mortality rate method. This is close to the culture-confirmed incidence (52 cases per 100,000 children !5 years old) and the estimate based on the meningitis incidence rate method (70 cases per 100,000 children !5 years old). For Samoa and the Solomon Islands, which have higher mortality rates for children !5 years old than does Tonga (37 deaths per 1000 live births in Samoa and 76 deaths per 1000 live births in the Solomon Islands), the true ratio of pneumonia to meningitis is probably somewhere between 5:1 and 1:1. The Hib meningitis incidence, calculated using the 1:1 ratio and the under-5 mortality rate method, gives an annual incidence of 236 cases per 100,000 children !5 years old for both countries. This would probably be an overestimate.
The estimated range of cases of and deaths due to Hib meningitis and Hib pneumonia, calculated using the meningitis incidence rate method and both the standard Hib pneumonia/ Hib meningitis ratio of 5:1 and a more conservative ratio of 1:1, is shown in table 4. The number of cases and deaths differs by up to 3-fold depending on the ratio used, because higher ratios impute higher Hib pneumonia rates for fixed or known Hib meningitis rates than do lower ratios.
Other estimates of Hib disease burden. Estimates of the burden of Hib disease for PICs are summarized in table 5. The quality of data, ability of the laboratory to isolate Hib, and LP rate from French Polynesia are unknown, so this rate may be a substantial underestimate of the true Hib burden. Data from Melanesian and Polynesian countries are of good quality and reasonably consistent, with estimates of the incidence of Hib meningitis ranging from 54 to 94 cases per 100,000 children aged !5 years. However, the quality of the data is insufficient to provide a regional estimate for Micronesia.
Cost of Hib immunization. Based on a cost of US$7.50 for 3 doses of Hib vaccine per child (the current United Nations Children's Fund price), approximate annual costs to immunize each country's birth cohort are shown in table 6. These costs exclude vaccine wastage, extra vaccine delivery costs, and any catch-up program that might take place.
DISCUSSION
The Hib meningitis incidence rates estimated in all 4 PICs using the Hib RAT were similar. These estimates are consistent with other data and suggest that the annual Hib meningitis incidence in all PICs is between 70 and 100 cases per 100,000 children !5 years old. This is higher than the weighted worldwide incidence of Hib meningitis of 60 cases per 100,000 children aged !5 years in developing countries [1] , higher than rates reported from sub-Saharan Africa [18] , and much higher than rates reported from Asia [19, 20] .
The disease burden estimates for the 2 main ethnic regions, c This is not based on local data and reflects the under-5 mortality rate. This is estimated from the proportion of deaths due to ALRI [11] . d It is assumed that 13% of all ALRI deaths in children aged !5 years were due to Hib. This is not based on local data but based on a review of the literature by the developers of the RAT [11] . e The Hib pneumonia case fatality rate is not based on local data and reflects the under-5 mortality rate. This is estimated from the proportion of deaths due to ALRI and the proportion of these deaths which may be due to Hib [11] . This is estimated to be 5% for Samoa and Tonga, and 10% for Solomon Islands. f The Hib meningitis case fatality rate of 10% for the Solomon Islands and Tonga and 14% for Samoa was calculated from Ministry of Health and pediatric discharge data. g Calculated using the Hib pneumonia/Hib meningitis ratio of 5:1. Melanesia and Polynesia, appear to be similar, but there are insufficient data to comment on the disease burden estimate for Micronesia. All of the Micronesian countries, other than Kiribati, have already introduced Hib vaccine. Thus, although the Kiribati estimate was based on a single isolate, the overall incidence of meningitis, the high case fatality rate associated with meningitis (29% of cases), and the high rates of neurological sequelae following meningitis (30% of cases), suggest that Kiribati is likely to have a substantial burden of Hib meningitis.
In each country visited, Hi was the most common organism isolated from CSF samples obtained from children with meningitis. Although all PICs visited used expired human blood for preparation of culture media, which is not recommended [21] , the rates of culture-confirmed Hib disease were high. These rates may also be an underestimate, considering that optimal laboratory practices were not undertaken in any of the PICs visited, even though these rates were adjusted to some extent by using the RAT. However, the impact of the use of human blood for isolating Hib on these rates needs to be clarified. Even without taking into account the effect of using the RAT, these data suggest that Hib causes a substantial burden of disease in PICs.
The Hib RAT provides a quick, simple, and relatively reliable method to estimate the true burden of Hib disease in those developing countries where existing surveillance and laboratory data are of reasonable quality [11] . The meningitis incidence rate method is likely to be more accurate than the under-5 mortality rate method, given that the former is based on local data and relies on fewer major assumptions than does the latter. The assumptions of each method may lead to inaccuracies in disease burden estimates, but all assumptions in the present study were conservative. The estimate of a 5:1 ratio of Hib pneumonia cases to Hib meningitis cases is based on only 2 studies, each from very different developing countries [8, 9] . The relative rarity of bacterial pneumonia and Hib pneumonia in developed countries suggests that, in those countries, the Hib pneumonia/Hib meningitis ratio is 1:1 or lower; therefore, universal application of the ratio of 5:1 is clearly inappropriate and, in countries with low under-5 mortality rates, an Hib pneumonia/Hib meningitis ratio of 1:1 would be more appropriate. In settings where available meningitis data allow the meningitis incidence rate method to be applied with reasonable confidence (such as in the PICs discussed the present study), the alternative method, working back from childhood mortality rates, provides a novel approach to estimating the Hib pneumonia/Hib meningitis ratio. If too high a ratio is used, the meningitis incidence will be underestimated, because the method relies on first estimating the Hib pneumonia rate from the under-5 mortality rate and then dividing by the ratio to derive the Hib meningitis estimate. This appears to have happened in the present study, when the ratio of 5:1 was applied to data from Tonga. A similar, but lesser, effect was seen in the Solomon Islands and Samoa, where the true ratio is likely to be closer to 5:1. If too low a ratio is used, the meningitis incidence will be overestimated for the opposite reasons; this appears to have happened in the present study with Samoa and the Solomon Islands, for each of which a ratio of 1:1 was used, resulting in unrealistically high Hib meningitis rate estimates. Thus, from the present study, it is reasonable to conclude that the Hib pneumonia/Hib meningitis ratio in Tonga is ∼1:1, and that, in the countries of Samoa and the Solomon Islands, in which the mortality rate is higher, the Hib pneumonia/Hib meningitis ratio is between 1:1 and 5:1. These findings should be considered when applying the Hib RAT in other settings. Universal Hib immunization is likely to be very effective in reducing Hib disease in those PICs not currently using Hib vaccine. Although non-type b Hi may be a common cause of pneumonia in some developing countries (a study from Papua New Guinea, using percutaneous lung aspirates, concluded that ∼60% of childhood pneumonia in that setting was caused by non-type b Hi [22] ), it is likely that most Hi disease in PICs is type b. This is illustrated by the substantial decrease in invasive Hi disease following the introduction of Hib vaccine in Fiji [5] . Most countries in the region have reasonable or high immunization coverage rates. During 2002, the coverage rates for the third dose of diphtheria-tetanus-pertussis vaccine were 100% of the population for Kiribati, 71% for the Solomon Islands, 96% for Samoa, and 90% for Tonga (O. Mansoor, personal communication). Moreover, the efficacy of conjugate Hib vaccine is known to be very high (195% after 3 doses) [6] . Even excluding the effect of herd immunity, the introduction of universal childhood Hib immunization would reduce the number of Hib meningitis and Hib pneumonia cases substantially. In PICs, the cost per case or per death prevented is relatively small. Factoring in treatment costs, including the large social cost of long-term care for the neurological damage experienced as a complication in р30% of meningitis cases, universal immunization in each country would be very costeffective, even using these conservative assumptions, at a cost of US$1000-US$10,000 per death prevented. Data from the present study suggest that Hib vaccination would be a good public health investment for both PICs and regional donornations to support.
